| Literature DB >> 18464779 |
Abstract
It's no gold rush, but dozens of players are emerging in personalized medicine, with biotechs, big and small, leading the way. Some big pharma companies and even payers remain skeptical, but economics aside, the real winners will be patients.Entities:
Mesh：
Year: 2008 PMID： 18464779 DOI： 10.1038/nbt0508-509
Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908